Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.
"I know too much. I don't know enough." Dr. Stephanie L. Graff interviews Dr. Kelly Shanahan, an OB/GYN living with metastatic breast cancer, about what it is like being a patient who is also a doctor.
ASCO Annual Meeting 2017: Symptom Reporting Extends Lives, Shorter Chemotherapy for Some Colon Cancer Patients, and Targeted Therapy in BRCA-Related Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Research released today covers how using a web-based system to report symptoms helps patients live longer, a shorter schedule of chemotherapy can be an option for certain people with colon cancer, and a targeted therapy may slow the growth of BRCA-related breast cancer.
ASCO Annual Meeting 2017: News on Breast Cancer, Prostate Cancer, TRK Fusion Protein Inhibition, Using Blood Tests to Screen for Cancer, and Genomic Testing
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Research highlights from today include pregnancy after breast cancer, abiraterone for prostate cancer, a new medication that targets a rare genetic abnormality, new blood test technology for cancer screening, and genomic testing.
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Here are some of today’s key research highlights, with a focus on enhancing survivors’ health.
From June 3 to June 7, oncology professionals from around the world will meet to discuss the latest in cancer research. If you can’t wait to learn about the latest research, check here for early highlights released in advance of the 2016 ASCO Annual Meeting.
Cancer does funny things to one’s sense of time. In this post, Margaret Zuccotti talks about how her diagnosis, treatment, and long-term survival of metastatic inflammatory breast cancer caused her to look at her calendar differently.
When Randy Hillard was diagnosed with metastatic stomach cancer in 2010 he was treated with a drug that increased overall survival to an average of 13 months. Now, nearly 5 years later, his unexpected survival has led to some unexpected issues.
For people with metastatic cancer, some aspects of life may be forgotten or considered unimportant. According to Dr. Dizon, this is especially the case with sexuality. In this post, Dr. Dizon shares the story of his patient, Elaine, and how she has dealt with the sexual side effects of breast cancer treatment.
After two decades of coping with advanced colorectal cancer, metastases in her lungs and liver, and a diagnosis of breast cancer, Margaret G. Werts, PhD, has learned how to maintain a sense of control and appreciate the small moments.